2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1708 Differential survival in patients with PTPN11-mutated AML is treatment specific

Vishvaas Immanuel Ravikumar, MD, Daniel Pollyea, MD2, Joshua F. Zeidner, MD3, Jennifer Saultz, DO4, Ronan Swords, MD5, Jeffrey Tyner, PhD6, Bill H Chang, MD, PhD7, Curtis Lachowiez, MD8
1 Oregon Health & Science University, Portland, Oregon, United States
2 University of Colorado School of Medicine, Aurora, Colorado, United States
3 University of North Carolina, Chapel Hill, North Carolina, United States
4 Knight Cancer Institute, Portland, Oregon, United States
5 Knight Cancer Institute, Portland, Oregon, United States
6 Knight Cancer Institute, Portland, Oregon, United States
7 Doernbecher Children's Hospital, Oregon Health & Science University, Portland, Oregon, United States
8 Knight Cancer Institute, Portland, Oregon, United States

Introduction 
In older or “unfit” adults with acute myeloid leukemia (AML), treatment with hypomethylating agents plus venetoclax (HMA+VEN) is standard frontline therapy. Emerging evidence, including preliminary PARADIGM trial findings, suggest that HMA+VEN may result in comparative response and survival vs. traditional intensive chemotherapy (IC) in adult patients irrespective of age or fitness, along with reduced toxicity and improved quality of life. However, certain groups remain high risk with HMA+VEN based on molecular risk classification, as reflected in the most recent ELN 2024 guidelines. As frontline HMA+VEN use expands to younger IC-eligible patients, it is important to identify genomic predictors that influence and may be predictive of response and survival to differing therapies. 

We previously demonstrated that patients with PTPN11-mutated (mut) AML experience inferior overall survival (OS) when treated with HMA+VEN (Ravikumar et al. ASH 2024). However, studies in patients receiving IC have shown conflicting results on the impact of PTPN11-mut following IC (Stasik et al. Blood Advances 2021, Fobare et al. Blood Advances 2022). This retrospective analysis compared OS in two cohorts of patients, an HMA+VEN treated cohort and an IC treated cohort, stratified by PTPN11 status (PTPN11-mut vs wild-type or WT), to determine if there was a differential treatment effect observed based on PTPN11 mutation status.  

Methods:  
Two treatment cohorts were included in the analysis. One cohort included patients treated with IC (n=415) enrolled on the Beat AML study at Oregon Health & Science University (OHSU), the other cohort included patients treated with HMA+VEN (n=279) at OHSU and two other academic medical centers. Molecular and clinical demographics were compared by PTPN11 status using both cohorts (n=694).  Within each cohort, OS was compared between patients with mutated vs. wild-type PTPN11. Categorical and continuous variables were compared with Fisher’s exact test with Benjamini-Hochberg FDR correction as appropriate. OS was assessed via Kaplan-Meier method and Cox-proportionate hazard modeling.   

Results: 
Overall, 9% (n=62) of patients had PTPN11-mut (n=22 in the HMA+VEN cohort; n=40 in the IC cohort). Between PTPN11-mut vs. PTPN11-WT patients, there was no significant difference in age (median: 60 vs. 63 years), sex (male: 50.0% vs. 56.4%), ELN 2022 risk (favorable: 38.7% vs. 25.3%, intermediate: 19.4% vs. 18.7%, adverse: 41.9% vs. 56.0%) or ELN 2024 risk classification (favorable: 53.2% vs. 47.2%, intermediate: 41.9% vs 37.2%, adverse: 4.8% vs 15.7%). Among patients with complete NGS and cytogenetic data (93%, n=647), analysis of molecular genetics showed that patients with PTPN11-mut had a significantly higher prevalence of co-occurring mutations in NPM1 (46.8% vs 23.7%, OR 2.82. FDR-adjusted p=0.005) and either NRAS or KRAS (29.0% vs 8.2%, OR 4.55, FDR-adjusted p<0.001). PTPN11-mut AML showed significantly higher prevalence of markers of monocytic differentiation, including CD14+ (35.6% vs. 14.3%, p<0.001), CD64+ (50.8% vs. 31.3%, p=0.007), co-occurring CD117- with CD64+ (28.8% vs. 6.3%, p<0.001), and co-occurring CD11b+ with CD64+ (45.8% vs. 17.9%, p<0.001) among PTPN11-mut patients. CD117+ was significantly higher in PTPN11-WT patients (91.5% vs. 74.6%, p<0.001).  

OS was assessed in the HMA+VEN and IC cohorts stratified by PTPN11 mutation status. Significantly shorter OS was observed following HMA+VEN in patients with vs. without PTPN11 mutations (median OS 4.8 vs. 12.5 months, p= 0.0059). This difference was not seen between PTPN11-mut vs PTPN11-WT in the IC cohort (median OS 41.9 vs. 52.8 months, p=0.51). Among patients with PTPN11-mut in the IC cohort, there was no significant difference in OS between those with co-occurring NPM1-mut vs NPM1-WT (median OS 45.11 vs. 16.97, p=0.547).   

Conclusions: 
Mutations in PTPN11 adversely affect OS in treatment with HMA+VEN but not IC. Patients with PTPN11-mut display an increase of immunophenotypic markers consistent with monocytic differentiation, which has previously been correlated with VEN resistance. As HMA+VEN use expands, and those eligible for IC are being considered for this therapy, variables that are prognostic for HMA+VEN but not IC, or vice versa, are critical to understand. PTPN11 mutation status should be considered for prognostication and when selecting frontline therapy.   

Vishvaas Immanuel Ravikumar, MD: No relevant conflicts of interest to declare.